• Edgewise Therapeutics swung to third-quarter 2026 net income of $1.17 billion, primarily reflecting a $1.35 billion gain on its sevasemten sale.
• Research and development expenses fell 16% to $31.58 million, while general and administrative expenses rose 55% to $14.57 million.
• Cash, cash equivalents and marketable securities totaled $1.74 billion at September 30, 2026.
• An EDG-7500 Phase 3 trial remains targeted for year-end 2026; the Phase 2 EQUINOX-HFpEF trial dosed its first patient.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Edgewise Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202611041601PR_NEWS_USPR_____LA88884) on November 04, 2026, and is solely responsible for the information contained therein.